PIK3CA kinase domain mutation identifies a subgroup of stage III colon cancer patients with poor prognosis. - Wikidata - wikimedia - TriplyDB

PIK3CA kinase domain mutation identifies a subgroup of stage III colon cancer patients with poor prognosis.

PIK3CA kinase domain mutation identifies a subgroup of stage III colon cancer patients with poor prognosis.

http://www.wikidata.org/entity/Q54568696

about

Prognostic Role of PIK3CA Mutation in Colorectal Cancer: Cohort Study and Literature Review Prognostic role of tumor PIK3CA mutation in colorectal cancer: a systematic review and meta-analysis Mutation profiling and microsatellite instability in stage II and III colon cancer: an assessment of their prognostic and oxaliplatin predictive value PIK3CA activating mutation in colorectal carcinoma: associations with molecular features and survival.PIK3CA mutations predict recurrence in localized microsatellite stable colon cancer KRAS mutation in lung metastases from colorectal cancer: prognostic implications.Phosphatidylinositol-3-kinase α catalytic subunit gene somatic mutations in bronchopulmonary neuroendocrine tumours.The prognostic role of KRAS, BRAF, PIK3CA and PTEN in colorectal cancer.Somatic mutation profiles in primary colorectal cancers and matching ovarian metastases: Identification of driver and passenger mutations.The prognostic value of Microsatellite Instability, KRAS, BRAF and PIK3CA mutations in stage II colon cancer patients.The homeobox gene MEIS1 is methylated in BRAF (p.V600E) mutated colon tumors.Predictive and prognostic analysis of PIK3CA mutation in stage III colon cancer intergroup trial.Biomarkers in precision therapy in colorectal cancer.PIK3CA in Colorectal Cancer.Important molecular genetic markers of colorectal cancer.Targeting the PI3K pathway for cancer therapy.Current and future biomarkers in the treatment of colorectal cancer.Personalized and precision medicine: integrating genomics into treatment decisions in gastrointestinal malignancies.PIK3CA gene mutation associated with poor prognosis of lung adenocarcinoma What can molecular pathology offer for optimal decision making?

P2860

Q24289005-83535EF0-7D45-49F6-A539-4FD50C3B94CC Q30248900-D37C89C5-9087-42DF-8738-C63F4DD99E87 Q34755943-AF0FD7E5-EBBA-4274-BFD2-CF87DBD0BC9B Q34778710-B6C2B19E-BE34-46AE-AB34-35091D512CBB Q35236785-639609FB-45E7-4E19-84F7-C32715B9E4C0 Q36528345-DC48C574-2509-4D4E-8D33-0F0062157F55 Q36642695-49E4ED4B-BA83-4B3E-9321-8BDFF3AFCC0A Q36896165-A7DAA7F5-73B1-4BEE-9E64-8FC86522AA9F Q37121274-8A4EFF61-0F00-43B9-B8E1-3FCD6AF7124D Q37170486-2D682656-D2FD-4AB1-993F-AF611CC09962 Q37288532-6DA1CB56-526B-4F75-A3FF-AB553F0B6F0A Q37360360-33B6C291-A5E9-400D-A5A9-DFFD15E52BC8 Q37609130-45B57576-CCF5-499C-BB36-7351F23BD197 Q37612390-6C087C89-4078-494E-8861-131B0D9D143D Q37619856-285F9B1D-B1C0-4825-B336-137F78F5BAF2 Q38019609-5C059A7B-39DF-457B-B085-1C3C68A81CB9 Q38787244-58A55E45-4873-49EC-A7BA-0FFD55A497E7 Q39453553-0397061A-167C-453E-962F-8DE7CF3DEA3A Q40656200-696C97CA-4CB1-4C86-9EE8-BAE7CD278570 Q51554436-C730B0AC-B62C-4E07-B0D2-6BF794AE8E6E

P2860

PIK3CA kinase domain mutation identifies a subgroup of stage III colon cancer patients with poor prognosis.

http://www.wikidata.org/entity/Q54568696

description

2011 nî lūn-bûn

@nan

2011年の論文

@ja

2011年学术文章

@wuu

2011年学术文章

@zh-cn

2011年学术文章

@zh-hans

2011年学术文章

@zh-my

2011年学术文章

@zh-sg

2011年學術文章

@yue

2011年學術文章

@zh

2011年學術文章

@zh-hant

name

PIK3CA kinase domain mutation ...... patients with poor prognosis.

@en

PIK3CA kinase domain mutation ...... patients with poor prognosis.

@nl

type

label

PIK3CA kinase domain mutation ...... patients with poor prognosis.

@en

PIK3CA kinase domain mutation ...... patients with poor prognosis.

@nl

prefLabel

PIK3CA kinase domain mutation ...... patients with poor prognosis.

@en

PIK3CA kinase domain mutation ...... patients with poor prognosis.

@nl

P1433

Q54568696-D12E60EF-F5BE-4612-8256-02AE84362EC8

P1476

Q54568696-63F3A06B-7BED-4E63-A09E-E3B50ADAA11A

P2093

Q54568696-0554D4A7-36F1-47AA-891C-2728501918E0

Q54568696-193030C1-8612-4698-B1E8-D308D8649A2A

Q54568696-2E5DDF9F-56DA-4AE5-8EAC-16F3B6AB7D8A

Q54568696-37465365-6DE0-4F36-8D38-BCDFE64F079D

Q54568696-420EFED5-AE63-438F-864A-D12044F14B7B

Q54568696-46CEC02C-236D-45B8-ABCC-311AFFBEF505

Q54568696-4C040BF2-522D-44E6-9D12-27E231F56A9E

Q54568696-5707806B-20AE-4979-9F3B-B1936AB669F5

Q54568696-76D1E95D-B22D-4D2A-B4B6-8635DDA72CCF

Q54568696-B7F83F21-CD4A-4EC1-84F1-87A17710F29E

P2860

Q54568696-0D224B84-CC5C-427F-BD7D-70D6EF433543

Q54568696-11745D2B-8061-4AA7-8ACB-E0DFB5FC4F29

Q54568696-156F19B6-7176-40F4-A07C-B6C6100D2CF8

Q54568696-218C5822-BBC0-4FCC-9029-7BFD1C65CA77

Q54568696-28B6CFC4-98A9-4A14-8A44-87A678C08ADC

Q54568696-294FDFBC-ACB0-44AE-BA5F-E7759EAAA4BA

Q54568696-30996AFC-D344-4568-868E-DE8B6D6B5FEF

Q54568696-3227BFF1-81B9-4688-8869-5A2F8CFA9461

Q54568696-374CD640-5AFD-4337-AD8D-81BD5AF78098

Q54568696-398E74E6-B5CB-401E-AF42-20025AC76A1D

P2888

Q54568696-842B11D1-333B-4F80-9B78-C8D1083E79BE

P304

Q54568696-F4F79D17-6D40-484F-AC48-CF310A654DFF

P31

Q54568696-0609194C-A98B-424C-9D71-8FF341193D5E

P356

Q54568696-843E3B47-3293-4EAA-8545-CD4E777B209B

P433

Q54568696-C78BBF56-FF68-4A4B-9E5B-F6284D3FA151

P478

Q54568696-C2200CD8-00EB-47E4-B305-6903648E17B7

P50

Q54568696-F5F740FD-1BC5-4BD1-841A-8BCE1B0484FD

P577

Q54568696-C683DD7E-43FE-4A8D-9283-B13EF5C95C61

P698

Q54568696-056E46E8-BF9F-4BC1-816E-D7207A7D84E8

P356

S13402-011-0054-4

P1433

Cellular Oncology

P1476

PIK3CA kinase domain mutation ...... patients with poor prognosis.

@en

P2093

A J C van den Brule

http://www.w3.org/2001/XMLSchema#string

Arantza Fariña Sarasqueta

http://www.w3.org/2001/XMLSchema#string

Cornelis J H van de Velde

http://www.w3.org/2001/XMLSchema#string

Eliane C M Zeestraten

http://www.w3.org/2001/XMLSchema#string

Gesina van Lijnschoten

http://www.w3.org/2001/XMLSchema#string

Hans Morreau

http://www.w3.org/2001/XMLSchema#string

Harm J T Rutten

http://www.w3.org/2001/XMLSchema#string

Ines J Goossens-Beumer

http://www.w3.org/2001/XMLSchema#string

Jan Willem T Dekker

http://www.w3.org/2001/XMLSchema#string

Peter J K Kuppen

http://www.w3.org/2001/XMLSchema#string

P2860

Mechanism of two classes of cancer mutations in the phosphoinositide 3-kinase catalytic subunit

The structure of a human p110alpha/p85alpha complex elucidates the effects of oncogenic PI3Kalpha mutations

Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis.

High frequency of mutations of the PIK3CA gene in human cancers

The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism

Differential enhancement of breast cancer cell motility and metastasis by helical and kinase domain mutations of class IA phosphoinositide 3-kinase.

A SNaPshot assay for the rapid and simple detection of four common hotspot codon mutations in the PIK3CA gene

Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer.

Cancer-specific mutations in PIK3CA are oncogenic in vivo

Current issues in adjuvant treatment of stage II colon cancer.

P2888

s13402-011-0054-4

P304

523-531

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S13402-011-0054-4

http://www.w3.org/2001/XMLSchema#string

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

34

http://www.w3.org/2001/XMLSchema#string

P50

P577

2011-08-10T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

21830111

http://www.w3.org/2001/XMLSchema#string